{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:36:47Z","timestamp":1778812607467,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ahjo.2026.100772","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:46:49Z","timestamp":1774514809000},"page":"100772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prevalence and characteristics of adults with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation in the USA"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5745-1636","authenticated-orcid":false,"given":"Michael G.","family":"Nanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance A.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads D.","family":"Faurby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise Lotte N.","family":"Husemoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riyanka","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamze","family":"Tombak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ahjo.2026.100772_bb0005","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ahjo.2026.100772_bb0010","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"New Engl J Med"},{"issue":"7347","key":"10.1016\/j.ahjo.2026.100772_bb0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ahjo.2026.100772_bb0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcvm.2019.00016","article-title":"Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease","volume":"6","author":"Aday","year":"2019","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ahjo.2026.100772_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2020.100130","article-title":"Inflammation and cardiovascular disease: from mechanisms to therapeutics","volume":"4","author":"Alfaddagh","year":"2020","journal-title":"Am J Prev Cardiol"},{"issue":"11","key":"10.1016\/j.ahjo.2026.100772_bb0030","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ahjo.2026.100772_bb0035","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2215\/CJN.03500412","article-title":"Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC","volume":"7","author":"Gupta","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100772_bb0040","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1523-1755.2004.00465.x","article-title":"Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease","volume":"65","author":"Oberg","year":"2004","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.ahjo.2026.100772_bb0045","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5527\/wjn.v3.i4.156","article-title":"Cardiovascular co-morbidity in chronic kidney disease: current knowledge and future research needs","volume":"3","author":"Alani","year":"2014","journal-title":"World J Nephrol"},{"issue":"4","key":"10.1016\/j.ahjo.2026.100772_bb0050","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.kint.2016.09.049","article-title":"Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review","volume":"91","author":"Mathew","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.ahjo.2026.100772_bb0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2840-13-26","article-title":"Residual macrovascular risk in 2013: what have we learned?","volume":"13","author":"Fruchart","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"issue":"46","key":"10.1016\/j.ahjo.2026.100772_bb0060","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","article-title":"Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy","volume":"43","author":"Ridker","year":"2022","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ahjo.2026.100772_bb0065","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin-6","volume":"2","author":"Tanaka","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"20","key":"10.1016\/j.ahjo.2026.100772_bb0070","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker","year":"2002","journal-title":"New Engl J Med"},{"issue":"9709","key":"10.1016\/j.ahjo.2026.100772_bb0075","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ahjo.2026.100772_bb0080","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","article-title":"A test in context: high-sensitivity C-reactive protein","volume":"67","author":"Ridker","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10289","key":"10.1016\/j.ahjo.2026.100772_bb0085","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"issue":"10384","key":"10.1016\/j.ahjo.2026.100772_bb0090","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ahjo.2026.100772_bb0095","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.123.066213","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among 13970 contemporary high-risk patients with statin intolerance","volume":"149","author":"Ridker","year":"2024","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ahjo.2026.100772_bb0100","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"New Engl J Med"},{"issue":"26","key":"10.1016\/j.ahjo.2026.100772_bb0105","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"New Engl J Med"},{"issue":"19","key":"10.1016\/j.ahjo.2026.100772_bb0110","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahjo.2026.100772_bb0115","series-title":"LODOCO highlights of prescribing information","author":"Agepha Pharma USA","year":"2023"},{"key":"10.1016\/j.ahjo.2026.100772_bb0120","series-title":"About the National Health and Nutrition Examination Survey","author":"Centers for Disease Control and Prevention","year":"2023"},{"issue":"184","key":"10.1016\/j.ahjo.2026.100772_bb0125","first-page":"1","article-title":"National Health and Nutrition Examination Survey, 2015-2018: sample design and estimation procedures","volume":"2","author":"Chen","year":"2020","journal-title":"Vital Health Stat."},{"key":"10.1016\/j.ahjo.2026.100772_bb0130","series-title":"NHANES questionnaires, datasets, and related documentation","author":"Centers for Disease Control and Prevention","year":"2023"},{"issue":"19","key":"10.1016\/j.ahjo.2026.100772_bb0135","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"New Engl J Med"},{"issue":"4s","key":"10.1016\/j.ahjo.2026.100772_bb0140","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.ahjo.2026.100772_bb0145","series-title":"Laboratory procedure manual high sensitivity C-reactive protein (hs-CRP)","year":"2017"},{"issue":"190","key":"10.1016\/j.ahjo.2026.100772_bb0150","first-page":"1","article-title":"National Health and Nutrition Examination Survey, 2017-March 2020 prepandemic file: sample design, estimation, and analytic guidelines","author":"Akinbami","year":"2022","journal-title":"Vital Health Stat 1"},{"key":"10.1016\/j.ahjo.2026.100772_bb0155","first-page":"193","article-title":"Confidence intervals for proportions with small expected number of positive counts estimated from survey data","volume":"24","author":"Korn","year":"1998","journal-title":"Surv. Methodol."},{"key":"10.1016\/j.ahjo.2026.100772_bb0160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ahj.2018.07.014","article-title":"High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States","volume":"204","author":"Pagidipati","year":"2018","journal-title":"Am. Heart J."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100772_bb0165","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00392-019-01511-0","article-title":"Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort","volume":"109","author":"Peikert","year":"2020","journal-title":"Clin. Res. Cardiol."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100772_bb0170","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/ppe.12409","article-title":"Prevalence and contributors to low-grade inflammation in three U.S. populations of reproductive age women","volume":"32","author":"Sjaarda","year":"2018","journal-title":"Paediatr. Perinat. Epidemiol."},{"issue":"46","key":"10.1016\/j.ahjo.2026.100772_bb0175","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1093\/eurheartj\/ehy723","article-title":"Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention?","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur. Heart J."},{"issue":"36","key":"10.1016\/j.ahjo.2026.100772_bb0180","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.ahjo.2026.100772_bb0185","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am. J. Kidney Dis."},{"issue":"18","key":"10.1016\/j.ahjo.2026.100772_bb0190","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-intensity statin use among patients with atherosclerosis in the U.S","volume":"79","author":"Nelson","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahjo.2026.100772_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2020.100010","article-title":"Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States","volume":"1","author":"Klimchak","year":"2020","journal-title":"Am J Prev Cardiol"},{"issue":"5","key":"10.1016\/j.ahjo.2026.100772_bb0200","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jacl.2016.06.011","article-title":"Prevalence of the American College of Cardiology\/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012","volume":"10","author":"Wong","year":"2016","journal-title":"J. Clin. Lipidol."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100772_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey","volume":"41","author":"Coresh","year":"2003","journal-title":"Am. J. Kidney Dis."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226000601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226000601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:30:36Z","timestamp":1777606236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602226000601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":41,"alternative-id":["S2666602226000601"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100772","relation":{},"ISSN":["2666-6022"],"issn-type":[{"value":"2666-6022","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and characteristics of adults with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation in the USA","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100772"}}